Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/120216
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMousa, A.en
dc.contributor.authorNaderpoor, N.en
dc.contributor.authorTeede, H.en
dc.contributor.authorDe Courten, M.en
dc.contributor.authorScragg, R.en
dc.contributor.authorDe Courten, B.en
dc.date.issued2015en
dc.identifier.citationMinerva Endocrinologica, 2015; 40(3):213-230en
dc.identifier.issn0391-1977en
dc.identifier.issn1827-1634en
dc.identifier.urihttp://hdl.handle.net/2440/120216-
dc.description.abstractObesity, type 2 diabetes, and cardiovascular disease (CVD) are the most common preventable causes of morbidity and mortality worldwide. Insulin resistance, which is a shared feature in these conditions, is also strongly linked to the development of polycystic ovary syndrome (PCOS), which is the most common endocrine disease in women of reproductive age and a major cause of infertility. Vitamin D deficiency has reached epidemic proportions worldwide, primarily due to the shift to sedentary, indoor lifestyles and sun avoidance behaviours to protect against skin cancer. In recent years, vitamin D deficiency has been implicated in the aetiology of type 2 diabetes, PCOS and CVD, and has been shown to be associated with their risk factors including obesity, insulin resistance, hypertension, as well as chronic low-grade inflammation. Treating vitamin D deficiency may offer a feasible and cost-effective means of reducing cardiometabolic risk factors at a population level in order to prevent the development of type 2 diabetes and CVD. However, not all intervention studies show that vitamin D supplementation alleviates these risk factors. Importantly, there is significant heterogeneity in existing studies with regards to doses and drug regimens used, populations studied (i.e. vitamin D deficient or sufficient), and the lengths of supplementation, and only few studies have directly examined the effect of vitamin D on insulin secretion and resistance with the use of clamp methods. Therefore, there is a need for well-designed large scale trials to clarify the role of vitamin D supplementation in the prevention of type 2 diabetes, PCOS, and CVD.en
dc.description.statementofresponsibilityA. Mousa, N. Naderpoor, H.J. Teede, M.P.J. De Courten, R. Scragg, B. De Courtenen
dc.language.isoenen
dc.publisherEdizioni Minerva Medicaen
dc.rightsCopyright Status Unknownen
dc.subjectVitamin D; obesity; insulin resistance; polycystic ovary syndrome; inflammation cardiovascular diseases; diabetes mellitusen
dc.titleVitamin D and cardiometabolic risk factors and diseasesen
dc.typeJournal articleen
dc.identifier.rmid0030094746en
dc.identifier.pubid431732-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS14en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.